12:15 PM EST, 11/15/2024 (MT Newswires) -- Altimmune ( ALT ) said Friday that data from its phase 1b testing of its pemvidutide drug candidate showed reductions in various inflammatory lipid species linked to cardiovascular risks in individuals with metabolic dysfunction-associated steatotic liver disease.

Pemvidutide, a balanced GLP-1/glucagon dual receptor agonist, is under development for treating metabolic dysfunction-associated steatohepatitis and obesity, according to the company.

pemvidutide was shown to reduce plasma concentrations of atherogenic lipoproteins and lipotoxic lipid classes associated, including a "rapid and significant reduction" in low-density lipoprotein particles in both the 1.8 and 2.4-milligram dosing groups compared to people receiving a placebo during the 12-week trial, Altimmune ( ALT ) said.

The company said that the weekly subcutaneous doses of pemvidutide led to significant reductions in lipids related to cardiovascular inflammation, liver inflammation, and atherosclerosis.

The findings highlight pemvidutide's potential to address co-morbidities of metabolic dysfunction-associated steatohepatitis, including atherosclerosis, heart disease, and metabolic syndrome.

Pemvidutide currently is being evaluated in a phase 2b trial in patients with steatotic liver disease, with study data due by mid-2025. Altimmune ( ALT ) presented the phase 1 data at The Liver Meeting of the American Association for the Study of Liver Diseases.

Price: 7.55, Change: -0.91, Percent Change: -10.76